January 16, 2023
The new article “Receptor occupancy assessment and interpretation in terms of quantitative systems pharmacology: nivolumab case study” by Dmitry Shchelokov and Oleg Demin Jr was published in mAbs journal at the end of December 2022.
Oleg Demin Jr comments on the article, “Mechanistic description of biomarkers and endpoints is necessary for accurate analysis of the clinical trial results and prediction of these outcomes by QSP modeling. One of these endpoints is target receptor occupancy which is measured in early clinical trials for therapeutic antibodies including monoclonal and bispecific ones, etc. In the published article we have shown that the method of target occupancy measurement can affect the results of clinical trials and their interpretation”.
About InSysBio
InSysBio is a group of Quantitative Systems Pharmacology (QSP) companies located in Edinburgh, UK (INSYSBIO UK LIMITED), Limassol, Cyprus (INSYSBIO CY Ltd) and Moscow, Russia (INSYSBIO LLC). InSysBio was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio’s innovative QSP approach has already become a part of the drug development process implemented by our strategic partners: there are more than 100 completed projects in collaboration with leaders of pharmaceutical industry. For more information about InSysBio, its solutions and services, visit www.insysbio.com
| ← | September 2020 | → | ||||
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
|
1
|
2
|
3
|
4
|
5
|
6
| |
|
7
|
8
|
9
1.
09 Sep 2020 14:59
InSysBio to update its Cytocon DB to version 1.2.6.7
InSysBio announces the new version of Cytocon DB 1.2.6.7! Cytocon DB team has reviewed 39 articles to implement the new data. It should be highlighted that the total number of reviewed articles within the Database has already exceeded 515!
|
10
|
11
|
12
|
13
|
|
14
|
15
|
16
1.
16 Sep 2020 14:54
InSysBio to take part in ACoP11
InSysBio announces its participation in Eleventh American Conference on Pharmacometrics (ACoP11) which is to be held in virtual format this year due to COVID-19 spread 9-13 November, 2020. The theme of ACoP11 is “Scaling New Heights.” InSysBio team is going to present 9 posters in frames of the Conference
|
17
|
18
|
19
|
20
|
|
21
|
22
|
23
1.
23 Sep 2020 10:26
InSysBio announces its collaboration with Genmab
The new partnership strives to evaluate the efficacy of a new oncology therapy – GEN1042 (DuoBody®-CD40x4-1BB)
[Moscow, Russia; Princeton, New Jersey, U.S. – 23.09.2020] InSysBio, one of the world’s pioneers of Quantitative Systems Pharmacology (QSP) modeling, announces its collaboration with Genmab, an international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer.
|
24
|
25
|
26
|
27
|
|
28
|
29
|
30
| ||||
Thank you for your message! We will get back to you shortly.
